65 results
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
3 Jun 24
Regulation FD Disclosure
7:00am
post-baseline assessment. All objective responses were confirmed per RECIST v 1.1. Data include patients on all schedules of azenosertib plus … period for an unrelated AE) and 28 were efficacy evaluable (had ≥1 post baseline-tumor assessment) Osteosarcoma, ZN-c3-003 Data cut-off: January 9
8-K
EX-99.1
ZNTL
Zentalis Pharmaceuticals Inc
9 Apr 24
Regulation FD Disclosure
4:30pm
-baseline assessment. All objective responses were confirmed per RECIST v 1.1. Data include patients on all schedules of azenosertib plus chemotherapy. Liu
8-K
EX-99.2
3tdse 72roi0ixtw
6 Nov 23
Zentalis Pharmaceuticals Reports Third Quarter 2023 Financial Results and Operational Updates
9:04am
8-K
EX-99.1
33v 6f9q1xa4j
13 Sep 23
Regulation FD Disclosure
7:00am
8-K
EX-99.1
uf36uy2o0 9ooqj740
9 Aug 23
Regulation FD Disclosure
4:15pm
8-K
EX-99.2
u8xbqt
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.3
qz6fqhz87noo6p4ft
6 Jun 23
Zentalis Announces Intermittent Azenosertib Monotherapy Dosing Nearly Doubles Efficacy Over Continuous Dosing
9:10am
8-K
EX-99.1
oi95 ah9ip4k1o
5 Jun 23
Regulation FD Disclosure
2:24pm
8-K
EX-99.2
2xezj4wff
5 Jun 23
Regulation FD Disclosure
2:24pm
PRE 14A
a5mxp2lpka80evt
18 Apr 23
Preliminary proxy
4:30pm
8-K
EX-99.2
rrhykxu
17 Apr 23
Zentalis announces preclinical data supporting Cyclin E1 as a predictive marker for azenosertib treatment at AACR Annual Meeting 2023
9:07am
8-K
EX-99.2
l2lhgz82dp2tsht710
9 Nov 22
Zentalis Pharmaceuticals Reports Third Quarter 2022 Financial Results and Operational Updates
7:04am